CHM 0.00% 1.0¢ chimeric therapeutics limited

However, there is every reason to believe that the Phase 1B...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,990 Posts.
    lightbulb Created with Sketch. 3424
    However, there is every reason to believe that the Phase 1B trials in the US sponsored by the COH are ongoing and that we will get data readouts on CHM-1101:-


    https://hotcopper.com.au/data/attachments/6342/6342057-386486f0d4a9c9a1905189f6b95a84b2.jpg

    https://hotcopper.com.au/data/attachments/6342/6342068-51b485f4d1c482d356c4f36e5274f1e3.jpg

    We know that our US counterparts are way ahead in cell therapies in terms of invention, experience and application. Hopper goes shopping in the US (and other locations) for interesting technologies and we are the licensees of such technologies. So, now that the GBM trials and our partnerships have yielded the data to pursue CLTX further, the story starts to get more interesting.

    Hopper is now wanting to initiate trials here in Aust where we need to establish a more user-friendly delivery system for our practitioners and get some of our own IP stamped on the technology. There is no indication that the ongoing trial at the City of Hope will not continue under its existing protocol and delivery system and for there not to be another interim readout. The trial is still actively RECRUITING as indicated above.



 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $9.951M
Open High Low Value Volume
1.1¢ 1.2¢ 1.0¢ $38.54K 3.639M

Buyers (Bids)

No. Vol. Price($)
9 2646760 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 729690 4
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.